Global Multicancer Early Detection Market - 2025 -2033
Industry Outlook
The global multi cancer early detection testing market reached US$ 1.67 billion in 2023, with a rise of US$ 1.92 billion in 2024, and is expected to reach US$ 7.52 billion by 2033, growing at a CAGR of 16.5% during the forecast period 2025-2033.
The global multi-cancer early detection (MCED) testing market is experiencing rapid growth due to the growing global cancer burden and demand for accurate, non-invasive diagnostic solutions. Technological advancements in liquid biopsy, genomics, and AI-driven bioinformatics enable multiple cancer detection from a single blood sample, improving patient outcomes and survival rates. Despite challenges like high testing costs, limited regulatory approvals, and false positives, MCED presents significant opportunities in emerging markets, strategic collaborations, and precision oncology.
Market Dynamics: Drivers & Restraints
Driver: Rising Global Cancer Prevalence
The global cancer prevalence is driving the multi-cancer early detection (MCED) testing market, as it provides effective and comprehensive screening solutions. Healthcare systems prioritize early detection to improve survival rates and reduce treatment costs. MCED tests, such as liquid biopsy, offer the advantage of identifying multiple cancers at early stages, addressing the growing demand for efficient screening. This trend is driving the adoption and expansion of MCED technologies globally.
For instance, according to American Cancer Society, in 2024, global cancer prevalence remains high, with around 20 million new cases and 9.7 million deaths annually, while 53.5 million people are living within five years of a cancer diagnosis. Lung, breast, and colorectal cancers are the most common, and the lifetime risk of cancer is approximately 1 in 5 people. Rising cases, driven by aging populations and lifestyle factors, are fueling demand for early detection solutions like multi-cancer early detection (MCED) testing.
Restraint: Improving Sensitivity and Specificity
Current MCED tests need improvement, particularly for stage I cancer detection. Novel biomarkers and technologies like cfDNA methylation patterns and miRNAs, ultrasensitive sequencing, and PCR can increase sensitivity. Understanding the causes of false positives in healthy individuals and addressing physiological changes like aging, lifestyle habits, and inflammation is crucial for cancer-related biomarker effects.
Segment Analysis
The global multi cancer early detection testing market is segmented based on test type, cancer type, end user, and region.
Test Type:
The galleri test segment the expected to have 40.66% of the multi cancer early detection testing market share.
The Galleri test, developed by GRAIL, is a highly advanced blood-based screening solution for cancer detection. It uses next-generation sequencing and methylation pattern analysis to detect over 50 types of cancer from a single blood draw, often early before symptoms appear. Galleri's strong clinical validation, partnerships with healthcare providers, and integration into large-scale screening programs drive market adoption and accelerate the shift towards proactive and precision oncology.
For instance, GRAIL, a healthcare company, and Quest Diagnostics have announced a program to enhance provider access to GRAIL's Galleri multi-cancer early detection (MCED) test. The initial phase of the program allows providers to order the test directly from GRAIL through the Quest Diagnostics connectivity system. This system allows providers in the US to order and receive laboratory test reports electronically through Quest's Quanum laboratory portal and over 900 electronic health record (EHR) systems.
Geographical Analysis
The North America global multi cancer early detection testing market was valued at 42.1% market share in 2024
North America's Multi-Cancer Early Detection (MCED) Testing Market is thriving due to high cancer burden, robust healthcare infrastructure, and advanced diagnostics adoption. The region benefits from R&D investments, reimbursement frameworks, and awareness of early cancer detection benefits. Leading developers like GRAIL, Exact Sciences, and Guardant Health, along with regulatory support for innovative screening technologies, accelerate market growth. Rising demand for personalized medicine and liquid biopsy-based tests further strengthens North America's growth hub.
For instance, in June 2025, Guardant Health, a precision oncology company, received Breakthrough Device designation from the U.S. Food and Drug Administration for its Shield multi-cancer detection test. The methylation-based blood test is used for screening multiple cancer types in individuals aged 45 or older, who are at average risk for cancer.
Major Key Players
The major players in the multi cancer early detection testing market include GRAIL, Guardant Health, Exact Sciences , Burning Rock Biotech, Lucence Health, Foundation Medicine (Roche), AnchorDx, Freenome, and Niramai among others.
Key Developments
The global multi cancer early detection testing market reached US$ 1.67 billion in 2023, with a rise of US$ 1.92 billion in 2024, and is expected to reach US$ 7.52 billion by 2033, growing at a CAGR of 16.5% during the forecast period 2025-2033.
The global multi-cancer early detection (MCED) testing market is experiencing rapid growth due to the growing global cancer burden and demand for accurate, non-invasive diagnostic solutions. Technological advancements in liquid biopsy, genomics, and AI-driven bioinformatics enable multiple cancer detection from a single blood sample, improving patient outcomes and survival rates. Despite challenges like high testing costs, limited regulatory approvals, and false positives, MCED presents significant opportunities in emerging markets, strategic collaborations, and precision oncology.
Market Dynamics: Drivers & Restraints
Driver: Rising Global Cancer Prevalence
The global cancer prevalence is driving the multi-cancer early detection (MCED) testing market, as it provides effective and comprehensive screening solutions. Healthcare systems prioritize early detection to improve survival rates and reduce treatment costs. MCED tests, such as liquid biopsy, offer the advantage of identifying multiple cancers at early stages, addressing the growing demand for efficient screening. This trend is driving the adoption and expansion of MCED technologies globally.
For instance, according to American Cancer Society, in 2024, global cancer prevalence remains high, with around 20 million new cases and 9.7 million deaths annually, while 53.5 million people are living within five years of a cancer diagnosis. Lung, breast, and colorectal cancers are the most common, and the lifetime risk of cancer is approximately 1 in 5 people. Rising cases, driven by aging populations and lifestyle factors, are fueling demand for early detection solutions like multi-cancer early detection (MCED) testing.
Restraint: Improving Sensitivity and Specificity
Current MCED tests need improvement, particularly for stage I cancer detection. Novel biomarkers and technologies like cfDNA methylation patterns and miRNAs, ultrasensitive sequencing, and PCR can increase sensitivity. Understanding the causes of false positives in healthy individuals and addressing physiological changes like aging, lifestyle habits, and inflammation is crucial for cancer-related biomarker effects.
Segment Analysis
The global multi cancer early detection testing market is segmented based on test type, cancer type, end user, and region.
Test Type:
The galleri test segment the expected to have 40.66% of the multi cancer early detection testing market share.
The Galleri test, developed by GRAIL, is a highly advanced blood-based screening solution for cancer detection. It uses next-generation sequencing and methylation pattern analysis to detect over 50 types of cancer from a single blood draw, often early before symptoms appear. Galleri's strong clinical validation, partnerships with healthcare providers, and integration into large-scale screening programs drive market adoption and accelerate the shift towards proactive and precision oncology.
For instance, GRAIL, a healthcare company, and Quest Diagnostics have announced a program to enhance provider access to GRAIL's Galleri multi-cancer early detection (MCED) test. The initial phase of the program allows providers to order the test directly from GRAIL through the Quest Diagnostics connectivity system. This system allows providers in the US to order and receive laboratory test reports electronically through Quest's Quanum laboratory portal and over 900 electronic health record (EHR) systems.
Geographical Analysis
The North America global multi cancer early detection testing market was valued at 42.1% market share in 2024
North America's Multi-Cancer Early Detection (MCED) Testing Market is thriving due to high cancer burden, robust healthcare infrastructure, and advanced diagnostics adoption. The region benefits from R&D investments, reimbursement frameworks, and awareness of early cancer detection benefits. Leading developers like GRAIL, Exact Sciences, and Guardant Health, along with regulatory support for innovative screening technologies, accelerate market growth. Rising demand for personalized medicine and liquid biopsy-based tests further strengthens North America's growth hub.
For instance, in June 2025, Guardant Health, a precision oncology company, received Breakthrough Device designation from the U.S. Food and Drug Administration for its Shield multi-cancer detection test. The methylation-based blood test is used for screening multiple cancer types in individuals aged 45 or older, who are at average risk for cancer.
Major Key Players
The major players in the multi cancer early detection testing market include GRAIL, Guardant Health, Exact Sciences , Burning Rock Biotech, Lucence Health, Foundation Medicine (Roche), AnchorDx, Freenome, and Niramai among others.
Key Developments
- In July 2025, Fred Hutch Cancer Center launched Vanguard Study, a national study evaluating multi-cancer detection (MCD) blood tests for early detection of cancer in individuals aged 45 to 75, aiming to improve treatment outcomes.
- In August 2024, Exact Sciences announced that the first patient has joined its Multi-Cancer Early Detection Falcon Registry Real-World Evidence study at Baylor Scott & White, the largest not-for-profit health system in Texas.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Test Type
2.4. Snippet by Cancer Type
2.5. Snippet by End User
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Global Cancer Prevalence
3.1.1.2. Increasing Demand for Early Diagnosis
3.1.2. Restraints
3.1.2.1. Improving Sensitivity and Specificity
3.1.2.2. Limited Regulatory Approvals and Standardization
3.1.3. Opportunity
3.1.3.1. Expansion in Emerging Markets
3.1.3.2. Integration Of AI and Bioinformatics in MCED Testing
3.1.4. Impact Analysis
4. GLOBAL MULTI CANCER EARLY DETECTION TESTING MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with largest largest-selling Brand
4.1.3. Market leaders with established products & Services
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Force Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Pricing Analysis and Price Dynamics
5. GLOBAL MULTI CANCER EARLY DETECTION TESTING MARKET: BY TEST TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
5.1.2. Market Attractiveness Index, By Test Type
5.2. Galleri Test *
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. CancerSEEK
5.4. Others
6. GLOBAL MULTI CANCER EARLY DETECTION TESTING MARKET: BY CANCER TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
6.1.2. Market Attractiveness Index, By Cancer Type
6.2. Breast Cancer*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Colorectal Cancer
6.4. Lung Cancer
6.5. Blood Cancer
6.6. Prostate Cancer
6.7. Others
7. GLOBAL MULTI CANCER EARLY DETECTION TESTING MARKET: BY END USER
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
7.1.2. Market Attractiveness Index, By End User
7.2. Hospitals & Clinics*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Diagnostic Laboratories
7.4. Academic & Research Institutes
8. GLOBAL MULTI CANCER EARLY DETECTION TESTING MARKET REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.1.1. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. U.K.
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. Brazil
8.4.6.2. Argentina
8.4.6.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. China
8.5.6.2. India
8.5.6.3. Japan
8.5.6.4. South Korea
8.5.6.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. Grail (Illumina)*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.2.3. Historic and Forecasted Product Sales
10.1.2.4. Product Sales Volume
10.1.3. Financial Overview
10.1.3.1. Company Revenue
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.4.4. SWOT Analysis
10.2. Guardant Health
10.3. Exact Sciences
10.4. Burning Rock Biotech
10.5. Lucence Health
10.6. Foundation Medicine (Roche)
10.7. AnchorDx
10.8. Freenome
10.9. Niramai (LIST NOT EXHAUSTIVE)
11. ASSUMPTIONS AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Test Type
2.4. Snippet by Cancer Type
2.5. Snippet by End User
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Global Cancer Prevalence
3.1.1.2. Increasing Demand for Early Diagnosis
3.1.2. Restraints
3.1.2.1. Improving Sensitivity and Specificity
3.1.2.2. Limited Regulatory Approvals and Standardization
3.1.3. Opportunity
3.1.3.1. Expansion in Emerging Markets
3.1.3.2. Integration Of AI and Bioinformatics in MCED Testing
3.1.4. Impact Analysis
4. GLOBAL MULTI CANCER EARLY DETECTION TESTING MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with largest largest-selling Brand
4.1.3. Market leaders with established products & Services
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Force Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Pricing Analysis and Price Dynamics
5. GLOBAL MULTI CANCER EARLY DETECTION TESTING MARKET: BY TEST TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
5.1.2. Market Attractiveness Index, By Test Type
5.2. Galleri Test *
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. CancerSEEK
5.4. Others
6. GLOBAL MULTI CANCER EARLY DETECTION TESTING MARKET: BY CANCER TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
6.1.2. Market Attractiveness Index, By Cancer Type
6.2. Breast Cancer*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Colorectal Cancer
6.4. Lung Cancer
6.5. Blood Cancer
6.6. Prostate Cancer
6.7. Others
7. GLOBAL MULTI CANCER EARLY DETECTION TESTING MARKET: BY END USER
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
7.1.2. Market Attractiveness Index, By End User
7.2. Hospitals & Clinics*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Diagnostic Laboratories
7.4. Academic & Research Institutes
8. GLOBAL MULTI CANCER EARLY DETECTION TESTING MARKET REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.1.1. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. U.K.
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. Brazil
8.4.6.2. Argentina
8.4.6.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. China
8.5.6.2. India
8.5.6.3. Japan
8.5.6.4. South Korea
8.5.6.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. Grail (Illumina)*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.2.3. Historic and Forecasted Product Sales
10.1.2.4. Product Sales Volume
10.1.3. Financial Overview
10.1.3.1. Company Revenue
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.4.4. SWOT Analysis
10.2. Guardant Health
10.3. Exact Sciences
10.4. Burning Rock Biotech
10.5. Lucence Health
10.6. Foundation Medicine (Roche)
10.7. AnchorDx
10.8. Freenome
10.9. Niramai (LIST NOT EXHAUSTIVE)
11. ASSUMPTIONS AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
LIST OF TABLES
Table 1 Global Multi Cancer Early Detection Testing Market Value, By Test Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Multi Cancer Early Detection Testing Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Multi Cancer Early Detection Testing Market Value, By End User, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Multi Cancer Early Detection Testing Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Multi Cancer Early Detection Testing Market Value, By Test Type, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Multi Cancer Early Detection Testing Market Value, By Test Type, 2022-2033 (US$ Billion)
Table 7 Global Multi Cancer Early Detection Testing Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Multi Cancer Early Detection Testing Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 9 Global Multi Cancer Early Detection Testing Market Value, By End User, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Multi Cancer Early Detection Testing Market Value, By End User, 2022-2033 (US$ Billion)
Table 11 Global Multi Cancer Early Detection Testing Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Multi Cancer Early Detection Testing Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America Multi Cancer Early Detection Testing Market Value, By Test Type, 2022-2033 (US$ Billion)
Table 14 North America Multi Cancer Early Detection Testing Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 15 North America Multi Cancer Early Detection Testing Market Value, By End User, 2022-2033 (US$ Billion)
Table 16 North America Multi Cancer Early Detection Testing Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 Europe Multi Cancer Early Detection Testing Market Value, By Test Type, 2022-2033 (US$ Billion)
Table 18 Europe Multi Cancer Early Detection Testing Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 19 Europe Multi Cancer Early Detection Testing Market Value, By End User, 2022-2033 (US$ Billion)
Table 20 Europe Multi Cancer Early Detection Testing Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific Multi Cancer Early Detection Testing Market Value, By Test Type, 2022-2033 (US$ Billion)
Table 22 Asia-Pacific Multi Cancer Early Detection Testing Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 23 Asia-Pacific Multi Cancer Early Detection Testing Market Value, By End User, 2022-2033 (US$ Billion)
Table 24 Asia-Pacific Multi Cancer Early Detection Testing Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 South America Multi Cancer Early Detection Testing Market Value, By Test Type, 2022-2033 (US$ Billion)
Table 26 South America Multi Cancer Early Detection Testing Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 27 South America Multi Cancer Early Detection Testing Market Value, By End User, 2022-2033 (US$ Billion)
Table 28 South America Multi Cancer Early Detection Testing Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa Multi Cancer Early Detection Testing Market Value, By Test Type, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa Multi Cancer Early Detection Testing Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa Multi Cancer Early Detection Testing Market Value, By End User, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa Multi Cancer Early Detection Testing Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 Grail (Illumina): Overview
Table 34 Grail (Illumina): Product Portfolio
Table 35 Grail (Illumina): Key Developments
Table 36 Guardant Health: Overview
Table 37 Guardant Health: Product Portfolio
Table 38 Guardant Health: Key Developments
Table 39 Exact Sciences : Overview
Table 40 Exact Sciences : Product Portfolio
Table 41 Exact Sciences : Key Developments
Table 42 Burning Rock Biotech: Overview
Table 43 Burning Rock Biotech: Product Portfolio
Table 44 Burning Rock Biotech: Key Developments
Table 45 Lucence Health: Overview
Table 46 Lucence Health: Product Portfolio
Table 47 Lucence Health: Key Developments
Table 48 Foundation Medicine (Roche): Overview
Table 49 Foundation Medicine (Roche): Product Portfolio
Table 50 Foundation Medicine (Roche): Key Developments
Table 51 AnchorDx: Overview
Table 52 AnchorDx: Product Portfolio
Table 53 AnchorDx: Key Developments
Table 54 Freenome: Overview
Table 55 Freenome: Product Portfolio
Table 56 Freenome: Key Developments
Table 57 Niramai: Overview
Table 58 Niramai: Product Portfolio
Table 59 Niramai: Key Developments
Table 1 Global Multi Cancer Early Detection Testing Market Value, By Test Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Multi Cancer Early Detection Testing Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Multi Cancer Early Detection Testing Market Value, By End User, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Multi Cancer Early Detection Testing Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Multi Cancer Early Detection Testing Market Value, By Test Type, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Multi Cancer Early Detection Testing Market Value, By Test Type, 2022-2033 (US$ Billion)
Table 7 Global Multi Cancer Early Detection Testing Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Multi Cancer Early Detection Testing Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 9 Global Multi Cancer Early Detection Testing Market Value, By End User, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Multi Cancer Early Detection Testing Market Value, By End User, 2022-2033 (US$ Billion)
Table 11 Global Multi Cancer Early Detection Testing Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Multi Cancer Early Detection Testing Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America Multi Cancer Early Detection Testing Market Value, By Test Type, 2022-2033 (US$ Billion)
Table 14 North America Multi Cancer Early Detection Testing Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 15 North America Multi Cancer Early Detection Testing Market Value, By End User, 2022-2033 (US$ Billion)
Table 16 North America Multi Cancer Early Detection Testing Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 Europe Multi Cancer Early Detection Testing Market Value, By Test Type, 2022-2033 (US$ Billion)
Table 18 Europe Multi Cancer Early Detection Testing Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 19 Europe Multi Cancer Early Detection Testing Market Value, By End User, 2022-2033 (US$ Billion)
Table 20 Europe Multi Cancer Early Detection Testing Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific Multi Cancer Early Detection Testing Market Value, By Test Type, 2022-2033 (US$ Billion)
Table 22 Asia-Pacific Multi Cancer Early Detection Testing Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 23 Asia-Pacific Multi Cancer Early Detection Testing Market Value, By End User, 2022-2033 (US$ Billion)
Table 24 Asia-Pacific Multi Cancer Early Detection Testing Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 South America Multi Cancer Early Detection Testing Market Value, By Test Type, 2022-2033 (US$ Billion)
Table 26 South America Multi Cancer Early Detection Testing Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 27 South America Multi Cancer Early Detection Testing Market Value, By End User, 2022-2033 (US$ Billion)
Table 28 South America Multi Cancer Early Detection Testing Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa Multi Cancer Early Detection Testing Market Value, By Test Type, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa Multi Cancer Early Detection Testing Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa Multi Cancer Early Detection Testing Market Value, By End User, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa Multi Cancer Early Detection Testing Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 Grail (Illumina): Overview
Table 34 Grail (Illumina): Product Portfolio
Table 35 Grail (Illumina): Key Developments
Table 36 Guardant Health: Overview
Table 37 Guardant Health: Product Portfolio
Table 38 Guardant Health: Key Developments
Table 39 Exact Sciences : Overview
Table 40 Exact Sciences : Product Portfolio
Table 41 Exact Sciences : Key Developments
Table 42 Burning Rock Biotech: Overview
Table 43 Burning Rock Biotech: Product Portfolio
Table 44 Burning Rock Biotech: Key Developments
Table 45 Lucence Health: Overview
Table 46 Lucence Health: Product Portfolio
Table 47 Lucence Health: Key Developments
Table 48 Foundation Medicine (Roche): Overview
Table 49 Foundation Medicine (Roche): Product Portfolio
Table 50 Foundation Medicine (Roche): Key Developments
Table 51 AnchorDx: Overview
Table 52 AnchorDx: Product Portfolio
Table 53 AnchorDx: Key Developments
Table 54 Freenome: Overview
Table 55 Freenome: Product Portfolio
Table 56 Freenome: Key Developments
Table 57 Niramai: Overview
Table 58 Niramai: Product Portfolio
Table 59 Niramai: Key Developments
LIST OF FIGURES
Figure 1 Global Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Multi Cancer Early Detection Testing Market Share, By Test Type, 2024 & 2033 (%)
Figure 3 Global Multi Cancer Early Detection Testing Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 4 Global Multi Cancer Early Detection Testing Market Share, By End User, 2024 & 2033 (%)
Figure 5 Global Multi Cancer Early Detection Testing Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Multi Cancer Early Detection Testing Market Y-o-Y Growth, By Test Type, 2023-2033 (%)
Figure 7 Galleri Test Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 8 CancerSEEK Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 9 Others Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 10 Global Multi Cancer Early Detection Testing Market Y-o-Y Growth, By Cancer Type, 2023-2033 (%)
Figure 11 Breast Cancer Cancer Type in Global Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 12 Colorectal Cancer Cancer Type in Global Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 13 Lung Cancer Cancer Type in Global Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 14 Blood Cancer Cancer Type in Global Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 15 Prostate Cancer Cancer Type in Global Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 16 Others Cancer Type in Global Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 17 Global Multi Cancer Early Detection Testing Market Y-o-Y Growth, By End User, 2023-2033 (%)
Figure 18 Hospitals & Clinics End User in Global Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 19 Diagnostic Laboratories End User in Global Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 20 Academic & Research Institutes End User in Global Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 21 Global Multi Cancer Early Detection Testing Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 22 North America Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 23 North America Multi Cancer Early Detection Testing Market Share, By Test Type, 2024 & 2033 (%)
Figure 24 North America Multi Cancer Early Detection Testing Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 25 North America Multi Cancer Early Detection Testing Market Share, By End User, 2024 & 2033 (%)
Figure 26 North America Multi Cancer Early Detection Testing Market Share, By Country, 2024 & 2033 (%)
Figure 27 Europe Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 28 Europe Multi Cancer Early Detection Testing Market Share, By Test Type, 2024 & 2033 (%)
Figure 29 Europe Multi Cancer Early Detection Testing Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 30 Europe Multi Cancer Early Detection Testing Market Share, By End User, 2024 & 2033 (%)
Figure 31 Europe Multi Cancer Early Detection Testing Market Share, By Country, 2024 & 2033 (%)
Figure 32 Asia-Pacific Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 33 Asia-Pacific Multi Cancer Early Detection Testing Market Share, By Test Type, 2024 & 2033 (%)
Figure 34 Asia-Pacific Multi Cancer Early Detection Testing Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 35 Asia-Pacific Multi Cancer Early Detection Testing Market Share, By End User, 2024 & 2033 (%)
Figure 36 Asia-Pacific Multi Cancer Early Detection Testing Market Share, By Country, 2024 & 2033 (%)
Figure 37 South America Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 38 South America Multi Cancer Early Detection Testing Market Share, By Test Type, 2024 & 2033 (%)
Figure 39 South America Multi Cancer Early Detection Testing Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 40 South America Multi Cancer Early Detection Testing Market Share, By End User, 2024 & 2033 (%)
Figure 41 South America Multi Cancer Early Detection Testing Market Share, By Country, 2024 & 2033 (%)
Figure 42 Middle East and Africa Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 43 Middle East and Africa Multi Cancer Early Detection Testing Market Share, By Test Type, 2024 & 2033 (%)
Figure 44 Middle East and Africa Multi Cancer Early Detection Testing Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 45 Middle East and Africa Multi Cancer Early Detection Testing Market Share, By End User, 2024 & 2033 (%)
Figure 46 Grail (Illumina): Financials
Figure 47 Guardant Health: Financials
Figure 48 Exact Sciences : Financials
Figure 49 Burning Rock Biotech: Financials
Figure 50 Lucence Health: Financials
Figure 51 Foundation Medicine (Roche): Financials
Figure 52 AnchorDx: Financials
Figure 53 Freenome: Financials
Figure 54 Niramai: Financials
Figure 1 Global Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Multi Cancer Early Detection Testing Market Share, By Test Type, 2024 & 2033 (%)
Figure 3 Global Multi Cancer Early Detection Testing Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 4 Global Multi Cancer Early Detection Testing Market Share, By End User, 2024 & 2033 (%)
Figure 5 Global Multi Cancer Early Detection Testing Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Multi Cancer Early Detection Testing Market Y-o-Y Growth, By Test Type, 2023-2033 (%)
Figure 7 Galleri Test Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 8 CancerSEEK Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 9 Others Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 10 Global Multi Cancer Early Detection Testing Market Y-o-Y Growth, By Cancer Type, 2023-2033 (%)
Figure 11 Breast Cancer Cancer Type in Global Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 12 Colorectal Cancer Cancer Type in Global Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 13 Lung Cancer Cancer Type in Global Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 14 Blood Cancer Cancer Type in Global Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 15 Prostate Cancer Cancer Type in Global Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 16 Others Cancer Type in Global Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 17 Global Multi Cancer Early Detection Testing Market Y-o-Y Growth, By End User, 2023-2033 (%)
Figure 18 Hospitals & Clinics End User in Global Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 19 Diagnostic Laboratories End User in Global Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 20 Academic & Research Institutes End User in Global Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 21 Global Multi Cancer Early Detection Testing Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 22 North America Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 23 North America Multi Cancer Early Detection Testing Market Share, By Test Type, 2024 & 2033 (%)
Figure 24 North America Multi Cancer Early Detection Testing Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 25 North America Multi Cancer Early Detection Testing Market Share, By End User, 2024 & 2033 (%)
Figure 26 North America Multi Cancer Early Detection Testing Market Share, By Country, 2024 & 2033 (%)
Figure 27 Europe Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 28 Europe Multi Cancer Early Detection Testing Market Share, By Test Type, 2024 & 2033 (%)
Figure 29 Europe Multi Cancer Early Detection Testing Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 30 Europe Multi Cancer Early Detection Testing Market Share, By End User, 2024 & 2033 (%)
Figure 31 Europe Multi Cancer Early Detection Testing Market Share, By Country, 2024 & 2033 (%)
Figure 32 Asia-Pacific Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 33 Asia-Pacific Multi Cancer Early Detection Testing Market Share, By Test Type, 2024 & 2033 (%)
Figure 34 Asia-Pacific Multi Cancer Early Detection Testing Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 35 Asia-Pacific Multi Cancer Early Detection Testing Market Share, By End User, 2024 & 2033 (%)
Figure 36 Asia-Pacific Multi Cancer Early Detection Testing Market Share, By Country, 2024 & 2033 (%)
Figure 37 South America Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 38 South America Multi Cancer Early Detection Testing Market Share, By Test Type, 2024 & 2033 (%)
Figure 39 South America Multi Cancer Early Detection Testing Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 40 South America Multi Cancer Early Detection Testing Market Share, By End User, 2024 & 2033 (%)
Figure 41 South America Multi Cancer Early Detection Testing Market Share, By Country, 2024 & 2033 (%)
Figure 42 Middle East and Africa Multi Cancer Early Detection Testing Market Value, 2022-2033 (US$ Billion)
Figure 43 Middle East and Africa Multi Cancer Early Detection Testing Market Share, By Test Type, 2024 & 2033 (%)
Figure 44 Middle East and Africa Multi Cancer Early Detection Testing Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 45 Middle East and Africa Multi Cancer Early Detection Testing Market Share, By End User, 2024 & 2033 (%)
Figure 46 Grail (Illumina): Financials
Figure 47 Guardant Health: Financials
Figure 48 Exact Sciences : Financials
Figure 49 Burning Rock Biotech: Financials
Figure 50 Lucence Health: Financials
Figure 51 Foundation Medicine (Roche): Financials
Figure 52 AnchorDx: Financials
Figure 53 Freenome: Financials
Figure 54 Niramai: Financials
